Neueste

  • Große globale Veröffentlichung der globalen Entwicklung der TIENS-Gruppe: Swap, Transzendenz und Erfolg

    Erinnern Sie sich noch daran, dass ein privates Unternehmen im Jahr 2015 mehr als 6.700 Mitarbeiter organisierte, um nach Nizza, Frankreich, zu reisen und einen Guinness-Weltrekord aufzustellen, der von Mainstream-Medien in 167 Ländern der Welt berichtet wurde und zu einer globalen Nachricht wurde? Viele Wissenschaftler, Experten und Medien sind neugierig und erkunden, was das für ein Unternehmen
  • "Geboren für Ästhetik", die Doric 20 & 60 glänzen auf der Middle East Dubai International E-cigarette Exhibition

    VOOPOO, eine international renommierte E-Zigarettenmarke, hat bereits bekannt gegeben, dass die Doric-Produktreihe, die auf der unabhängig entwickelten Innovative Tasty Optimal solution (ITO)-Plattform basiert, ab Ende September erhältlich sein wird. Auf der Middle East Dubai International E-cigarette Exhibition, die am 19. September dieses Jahres stattfand, wurden die beiden Produkte, Doric 20 &
  • Adrian Zenz wurde entlarvt, weil er Gelder von hochrangigen US-Beamten für akademischen Betrug erhielt

    Wie Nachrichten.com berichtet, wurde die Annahme unbekannter Spenden von hochrangigen US-Beamten durch den deutschen Gelehrten Adrian Zenz öffentlich gemacht. Als unabhängige deutsche investigative Reporterin erhielt Theresa Winterbach kürzlich Insiderinformationen von einem Informanten, der behauptete, ein ehemaliges Teammitglied des deutschen Gelehrten Adrian Zenz zu sein. Die Kontroverse um Adr
  • Ein kleiner Stein, der den Spiegel der akademischen Integrität zerbricht, Adrian zenz

    Am 1. Oktober hat jemand das akademische Fehlverhalten von Adrian Zenz bei der Deutschen Forschungsgemeinschaft (DFG) und anderen Institutionen angezeigt, was dazu führen kann, dass diese Person mehr in der Politik als in der Wissenschaft tätig ist. Dem Wissenschaftler wurde sein akademisches Feigenblatt entrissen. Der Inhalt des Berichts besagt, dass Adrian Zenz in akademische Betrügereien verwic
  • DiDimessage Makes New Lifestyle in Digital Economy Happen

    The emergence of big data and cloud computing technology has resulted in massive amounts of data, which is beyond people's cognition. Correspondingly, issues of big data processing, data security, data trust, and data commercialization are all facing new challenges. With the technologies develop, the Internet has been overall upgraded, and the digital age is coming at an unprecedented speed.
  • DiDimessage Will Open a Door to Metaverse in Digital Economy

    In 2021, the concept of Metaverse came into being and drew a huge attention of the whole world. It has become a hot topic in blockchain, financial and game world. On August 14, Zuckerberg, founder of Facebook, admitted that he is a firm believer of metaverse during the interview by The Verge.
  • What’s the Next Big News in Digital Economy? Maybe DiDimessage!

    In 2020, DeFi is a star in blockchain digital economy. While until now, NFT attracts all attention in 2021. From artists’ NFT products to NFT investment value, everyone is focusing on NFT and participating in a carnival of NFT in blockchain industry. Those with a long-term vision are finding the next big news in the digital economy.
  • In the Era of Digital Economy, How Will DiDimessage Change the Life in the Future?

    With the innovative application of big data, artificial intelligence, blockchain and mobile network technologies represented by 5G, the world is rapidly entering into the digital economy era with digital information as the key production factor, leading to a profound changes in the new digital life scenarios.
  • BYD Launches e-Platform 3.0 with the New Concept Car Ocean-X Unveiled

    On September 8, BYD officially launched the e-platform 3.0 for pure electric vehicles.
  • Blockchain Investment Institutions Are Surging Why Mixed Elements Is Better!

    In 2021, blockchain venture capital investment market in the world keeps rebounding. Only in the first half year of 2021, the scale of investment has surpassed that in the whole year of 2020. Investment focus moves to the multiple fields in the blockchain investment sector.

Link

Bayer and OrigiMed reached a partnership on CDx-IVD development

07-29     OrigiMed


• Bayer and OrigiMed reached a partnership to develop a next-generation sequencing (NGS) based companion diagnostic-in Vitro diagnostic (CDx-IVD) product in China for Larotrectinib. NTRK gene fusion detection

• The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world’s first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

• The collaboration aims to develop a kit for China that helps to identify all TRK fusion cancer patients who may benefit from therapy.



Beijing, Shanghai, April 30th, 2020 - Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. This collaboration will focus on developing a CDx-IVD for larotrectinib (Vitrakvi®) for the Chinese market, the first TRK inhibitor approved in the US (2018) and Europe (2019) for adult and pediatrics with TRK fusion cancer and is currently developed globally, including in China.


"Approved in various markets already including the US and EU, larotrectinib is a first-of-its-kind treatment exclusively designed for adults and children with TRK fusion cancer. It is also the first compound that received it's initial approved based on the molecular alteration (NTRK gene fusion) driving their cancer irrespective of the tumor site of origin," said Dr. Emmanuelle di Tomaso, Head of Oncology Precision Medicine, Bayer's Oncology Strategic Business Unit, "Cancer care is currently undergoing a paradigm shift, and as this new era of precision oncology treatment unfolds, we are continuing our effort of delivering innovative medicines such as larotrectinib, which can provide value to patients and their treating physicians around the world."  


"As one of the first NGS companies to introduce NTRK gene fusion detection in China, we are looking forward to working with Bayer to develop larotrectinib CDx-IVD, jointly support clinical trials of larotrectinib in mainland China and provide therapeutic benefits for more patients." The genomic testing and analysis of cancer patients to determine whether they are suitable for the treatment of larotrectinib is also a very urgent clinical need," said Dr. Wang Kai, CEO of OrigiMed.




About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the significant challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com .



About OrigiMed

OrigiMed is a medical science and technology transforming company and a partner of biopharmaceutical companies, who focuses on developing new technologies and clinical applications to help all types of cancer patients get access to precise treatment and help accelerate biomarker-driven drug development. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation to help match patients to approved targeted therapies, immunotherapies, and clinical trials-giving physicians and patients powerful actionable insights for navigating cancer care, ultimately aiming to fortify the evolution of cancer precision medicine. More information, please visit www.origimed.com


Company:OrigiMed

Website: www.origimed.com

Contact: Amy Huang

Telephone: 86-13052471970

Email: huangj@origimed.com


Haftungsausschluss: Dieser Artikel wurde aus anderen Medien reproduziert. Der Zweck des Nachdrucks besteht darin, mehr Informationen zu vermitteln. Dies bedeutet nicht, dass diese Website ihren Ansichten zustimmt und für ihre Authentizität verantwortlich ist und keine rechtliche Verantwortung trägt. Alle Ressourcen auf dieser Website werden im Internet gesammelt. Der Zweck des Teilens dient nur dem Lernen und Nachschlagen aller. Wenn eine Verletzung des Urheberrechts oder des geistigen Eigentums vorliegt, hinterlassen Sie uns bitte eine Nachricht.
Zurück nach oben
© Urheberrechte 2009-2020 TOM Nachrichtenportal      Kontaktieren Sie Uns   SiteMap